Preclinical studies showed that CD56 CAR + T cells were capable of killing in vitro CD56+ SCLC tumor cells and when tested against CD56 + human xenograft SCLC models, they were able to inhibit tumor growth in vivo [32]. The gene discussed is NCAM1; the disease is neoplasm.